The dapagliflozine-type 2 sodium glucose cotransporter inhibitor in the treatment of diabetes mellitus type 2
E-mail
natasa.neskovic977@gmail.com
djenic.cigota@gmail.com
Ustanova
Health Center Uzice
Special Hospital for Thyroid and Metabolism Disorders Zlatibor
Reference
Đukić A, Đurđević P, Živančević-Simonović S, Jurišić V, Mijatović Lj. Opšta patološka fiziologija. Beograd; Intergraf: 2002; 400–408.
International Diabetes Federation. IDF Diabetes Atlas, 7th ed. International Diabetes Federation: Brussels, Belgium: 2015; available at: http://www.diabetesatlas.org
Stark Casagrande, S., Fradkin, J., Saydah, S., Rust, K. and Cowie, C. (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 36: 2271–2279.
Sažetak
The dapagliflozine-type 2 sodium glucose cotransporter inhibitor in the treatment of diabetes mellitus type 2
Ključne reči
Medicinski glasnik
Autor